Emerging therapeutic agents for cervical cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 3, 2009, Pages 196-206

  Cornelio, Daniela B ^a,b,c,d   Roesler, Rafael ^a,c   Schwartsmann, Gilberto ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c National Institute for Translational Medicine INCT TM   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cervical cancer; Growth factors; Targeted therapy

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ADAMANTANE DERIVATIVE; ANGELOYL SUBSTITUTED INGENANE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLICE INHIBITORY PROTEIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYBRID PROTEIN; HYDROXYUREA; INTERLEUKIN 10; INTERLEUKIN 19; LY 29400; NU 6140; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; ROSCOVITINE; TANESPIMYCIN; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN B ANTAGONIST; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; ADVANCED CANCER; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; DRUG TARGETING; EARLY CANCER; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PATENT; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SOLID TUMOR; SURVIVAL TIME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VERRUCA VULGARIS; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOTHERAPY; PATENTS AS TOPIC; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 70350778511     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209789206887     Document Type: Review

References (74)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2006; 56: 106-130.
3. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 2001; 358: 781-786.
4. Long HJ 3rd. Management of metastatic cervical cancer: Review of the literature. J Clin Oncol 2007; 25(20): 2966-2974.
5. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340 (15): 1137-1143.
6. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiataion and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340 (15): 1154-1161.
7. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18 (8): 1606-1613.
8. Thomas GM. Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy. N Engl J Med 1999; 340 (15): 1198-1200.
9. Ryu HS, Kang SB, Kim KT, et al. Efficacy of different types of treatment in FIGO stage 1B2 cervical cancer in Korea: Results of a multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer 2007; 17: 132-136.
10. Chang TC, Lai CH, Hong JH, et al. Randomized trial of neo-adjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol 2000; 18: 1740-1747.
11. Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: Results from the Italian multicenter randomized study. J Clin Oncol 2002; 20: 179-188.
12. Tierney JF, Stewart LA, Parmar MK. Can the published data tell us about the effectiveness of neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix? Eur J Cancer 1999; 35: 406-409.
13. Neoadjuvant chemotherapy for locally advanced cervical cancer meta-analysis collaboration. Neoadjuvant chemotherapy for locally-advanced cervical cancer: A systematic review and meta-analysis of individual patient data from 21 randomized trials. Eur J Cancer 2003; 39: 2470-2486.
14. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluoracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17(5): 1339-1348.
15. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340(15): 114-153.
16. Lanciano R, Calkins A, Bundy B, et al. A randomized comparison of radiation plus weekly cisplatin versus protacted venous infusion 5-FU in combination with concurrent radiation in advanced cervix cancer: A GOG Study. J Clin Oncol 2005; 23: 8289-8295.
17. Micheletti E, LaFace B, Bianchi E, et al. Continuous infusion of carboplatin during conventional radiotherapy treatment in advanced squamous carcinoma of the cervix uteri IIB-IIIB (UICC): A phase I/II and pharmacokinetic study. Am J Clin Oncol 1997; 20: 613-620.
18. Higgins RV, Naumann WR, Hall JB, et al. Concurrent weekly carboplatin with radiation therapy in the primary treatment of cervix cancer. Gynecol Oncol 2003; 89: 499-503.
19. Tseng CJ, Chang CT, Lai CH, et al. A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the uterine cervix. Gynecol Oncol 1997; 66: 52-58.
20. Lee MY, Wu HG, Kim K, et al. Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2007; 106: 95-99.
21. Boualga K, Aksil N, Ayad M, et al. Phase I/II study of Gemcitabine and concomitant radiotherapy in locally advanced carcinoma of the cervix. ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (16): Part I of II, 5142.
22. Bhatt ML, Matin A, Srivastava M, et al. Evaluation of Gemcitabine versus Cisplatin in adjunct to radiotherapy in locally advanced carcinoma of the uterine cervix. ASCO Annual Meeting Proceedings. J Clin Oncol 2007; 25 (18): Part 1, 16012.
23. Gatcliffe TA, Tewari KS, Shah A, et al. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer. Gynecol Oncol 2009; 112(1):85-89.
24. Ackermann S, Beckmann MW, Thiel F, Bogenrieder T. Topotecan in cervical cancer. Int J Gynecol Cancer 2007; 17(6): 1215-1223.
25. Perez CA, Grigsby PW, Nene SM, et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with radiation alone. Cancer 1992; 69(11): 2796-2806.
26. McQuay HJ, Carroll D, Moore RA. Radiotherapy for painful bone metastases: A systematic review. Clin Oncol (R Coll Radiol) 1997; 9:150-154.
27. Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 2003; 9: 425-432.
28. Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group study. Gynecol Oncol 1990; 39: 332-336.
29. McGuire WP III, Arseneau J, Blessing JA, et al. A andomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 1462-1468.
30. Long HJ III. Management of metastatic cervical cancer: Review of the literature. J Clin Oncol 2007; 25: 2966-2974.
31. Omura GA, Blessing JA, Vacarelli L, et al. Randomized trial of cisplatin versus cisplatin with mitolactol versus cisplatin plus ifosfmide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 1997; 15: 165-171.
32. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 3113-3119.
33. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 2005; 23: 4626-4633.
34. Ramm K, Vergote IB, Kaern J, et al. Bleomycin-ifosfamidecisplatinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look. Gynecol Oncol 1992; 46: 203-207.
35. Murad AM, Triginelli SA, Ribalta JCL. Phase II of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994; 12: 55-59.
36. Zanetta G, Fei F, Parma G, et al. Paclitaxl, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. Ann Oncol 1999; 10: 1171-1174.
37. Stornes I, Mejlhom I, Jakobsen A. A phase II trial of ifosfamide, 5-fluoracil, and leucovorin in recurrent uterine cervical cancer. Gynecol Oncol 1994; 55: 123-125.
38. Fanning J, Ladd C, Hilgers RD. Cisplatin, 5-fluoracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer. Gynecol Oncol 1995; 56: 235-238.
39. Yarden Y. The EGFR family and its ligands in human cancer: Signaling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(Suppl 4): 3-8.
40. Bellone S, Frera G, Landolfi G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007; 106(3): 513-520.
41. Hale RJ, Buckley CH, Gullick WJ, et al. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993; 46(2): 149-153.
42. Kim GE, Kim YB, Cho NH, et al. Synchronous coexpression of epidermal growth factor receptor and cycloxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival. Clin Cancer Res 2004; 10(4): 1366-1374.
43. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85(16): 1327-1333.
44. Liang K, Ang KK, Milas L, et al. The epidermal growth factor receptor mediates radioresistance. Int J Rad Oncol 2003; 57(1): 246-254.
45. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23(11): 2445-2459.
46. Bellone S, Frera G, Landolfi G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol 2007; 106(3): 513-520.
47. Gonçalves A, Fabbro M, Lhomme C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008; 108(1): 42-46.
48. Nogueira-Rodrigues A, do Carmo CC, Viegas C, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res 2008; 14(19): 6324-6329.
49. Dai Q, Ling YH, Lia M, et al. Enhanced sensitivity to the HER1/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 2005; 11(4): 1572-1578.
50. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004; 25(4): 581-611.
51. Loncaster J, Cooper R, Logue J, et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced clarcinoma of the cervix. Br J Cancer 2000; 83: 620-625.
52. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995; 87(16): 1237-1245.
53. Zhang XY, Zhang HY, Zhang PN, Lu X, Sun H. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur J Obstet Gynecol Reprod Biol 2008; 139(2): 237-244.
54. Lee CM, Fuhrman CB, Planelles V, et al. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin Cancer Res 2006; 12(1): 250-256.
55. Schwock J, Pham NA, Cao MP, Hedley DW. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitroand in vivo. Cancer Chemother Pharmacol 2008; 61(4): 669-681.
56. Bisht KS, Bradbury CM, Mattson D, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003; 63(24): 8984-8995.
57. Wesierska-Gadek J, Wandl S, Kramer MP, Pickem C, Krystof V, Hajek SB. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J Cell Biochem 2008; 105(5): 1161-1171.
58. Pennati M, Campbell AJ, Curto M, et al. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation. Mol Cancer Ther 2005; 4(9): 1328-1337.
59. Maliekal TT, Bajaj J, Giri V, Subramanyam D, Krishna S. The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene 2008; 27(38): 5110-5114.
60. Wang L, Qin H, Chen B, Xin X, Li J, Han H. Overexpressed active Notch1 induces cell growth arrest of HeLa cervical carcinoma cells. Int J Gynecol Cancer 2007; 17(6): 1283-1292.
61. Yu H, Huang SL, Zhao XP, Lu J, Qian GX, Ge SF. Effect of CRE-dependent RNA interference targeting Notch1 on proliferation of cervical cancer cell line HeLa. Ai Zheng 2007; 26(2): 148-153.
62. Johnston, P. G., Longley, D.: US20080171051 (2008).
63. Schlegel, R.: US20080113340 (2008).
64. Ogbourne, S. M., Suhrbier, A.: US20080187513 (2008).
65. Monahan, J. E., Zhao, X., Chen, Y., Glatt, K., Kamatkar, S.: US20080286781 (2008).
66. Fisher, P. B., Sarkar, D.: US20080213220 (2008).
67. Rohllf, C., Stamps, A.: WO2008104804 (2008).
68. Nash, A., Dunlop, F. M., Baca, M., Fabri, L. J., Scotney, P. D.: US20080260729 (2008).
69. Chandrasekher, Y. A., Mckernan, P. A.: US20070269407 (2007).
70. Regts, D. G., Holtrop, M., Wilschut, J. C., Daemen, C. A.: US20070166328 (2007).
71. Cheung, L. Y.: US20060029613 (2006).
72. Chang, H., Liao, C., Cheng, W.: US20060039919 (2006).
73. Pfahl, M., Lu, X., Rideout, D., Zhang, H.: US20046825226 (2004).
74. Chandrasekher, Y. A., Mckernan, P. A.: US20030161811 (2003).